Observational studyClinical infectious diseases : an official publication of the Infectious Diseases Society of America2024
Distinct Clinical Endpoints of Staphylococcus aureus Bacteraemia Complicate Assessment of Outcome.
Observational study in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies Pathways for Host-Directed Therapeutic Targeting.The Journal of infectious diseases · 2025Pooled it
- Rationalizing Heterogeneity in Staphylococcus aureus Bacteremia: Current Progress and Future Goals.The Journal of infectious diseases · 2026Review
- Clinical characteristics of bloodstream infections in the patients receiving anti-IL-6 receptor antibody.Infection · 2026Article
- Impact of Methicillin Resistance on Outcomes ofOpen forum infectious diseases · 2026Article
- Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Respiratory Virus Coinfection Is a Risk Factor for Adverse Outcomes DuringOpen forum infectious diseases · 2026Article
- Emergence of a methicillin-susceptibleFrontiers in cellular and infection microbiology · 2026Article
- Clinical characteristics and efficacy of short-course antibiotic therapy forMicrobiology spectrum · 2025Article
- Construction and validation of a predictive in-hospital mortality nomogram in patients with staphylococcus aureus bloodstream infection.Scientific reports · 2025Article
- The Clinical and Molecular Characteristics of Community-AssociatedOpen forum infectious diseases · 2025Article
- Identification and validation of clinical phenotypes inEClinicalMedicine · 2025Article
- Incidence, Clinical Characteristics and Outcomes of PersistentInfection and drug resistance · 2025Article
- Clinical Subphenotypes of Staphylococcus aureus Bacteremia.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundWe aimed to test the hypothesis that development of metastatic infection represents a distinct clinical endpoint from death due to Staphylococcus aureus bacteremia (SAB).
methodsWe conducted a retrospective observational study of adults with SAB between 20 December 2019 and 23 August st2022 (n = 464). Simple logistic regression, odds ratios, and z-scores were used to compare host, clinical, and microbiologic features.
resultsCo-occurrence of attributable mortality and metastatic infection was infrequent. Charlson Comorbidity Index and age were strongly associated with attributable mortality, but not metastatic infection. We compared patients with fatal SAB (without clinically-apparent metastatic complications, 14.4% of cohort), metastatic SAB (without attributable mortality, 22.2%), neither complication (56.7%), and overlapping fatal/metastatic SAB (6.7%). Compared to SAB without complications, fatal SAB was specifically associated with older age and multi-morbidity. Metastatic SAB was specifically associated with community acquisition, persistent fever, persistent bacteremia, and recurrence. Endocarditis was over-represented in the fatal/metastatic SAB overlap group, which shared patient characteristics with fatal SAB. In contrast to other (predominantly musculoskeletal) metastatic complications, endocarditis was associated with increased mortality, with death occurring in older multi-morbid patients later after SAB onset.
conclusionsPatients with SAB experience distinct clinical endpoints: (i) early death, associated with multi-morbidity and age; (ii) metastatic (predominantly musculoskeletal) SAB; (iii) endocarditis, associated with late death occurring in older people with multi-morbidity, and (iv) bacteraemia without complications. These distinctions could be important for selecting appropriate outcomes in clinical trials: different interventions might be required to reduce mortality versus improve clinical response in patients with metastatic SAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.